INIS
doses
100%
patients
100%
reviews
100%
efficiency
100%
chemotherapy
100%
anemias
100%
erythropoiesis
100%
range
47%
data
23%
levels
11%
comparative evaluations
11%
labelling
11%
clinical trials
5%
blood cells
5%
production
5%
europe
5%
inclusions
5%
statistics
5%
adjustments
5%
hemoglobin
5%
Keyphrases
Erythropoiesis-stimulating Agents
100%
Cancer-related Anemia
100%
Dose Efficiency
100%
Darbepoetin Alfa
58%
Short-acting
58%
Dose Increase
25%
Withholding
16%
Epoetin Alfa
16%
Statistical Heterogeneity
16%
Clinical Practice
8%
Randomized Clinical Trial
8%
Europe
8%
Patient Characteristics
8%
Inclusion Criteria
8%
Metaanalysis
8%
Best Available Evidence
8%
Hemoglobin Level
8%
Descriptive Statistics
8%
Good Quality
8%
Patients Included
8%
Clinical Patients
8%
Dose Adjustment
8%
I(2)
8%
Dose Ratio
8%
Potential Dose
8%
Medical Practice
8%
Starting Dose
8%
Head-to-head Trials
8%
Data Pooling
8%
Narrative Summary
8%
Statistical Homogeneity
8%
Practice Characteristics
8%
Red Blood Cell Production
8%
Hierarchy of Evidence
8%
Epoetin theta
8%
Epoetin zeta
8%
Haemoglobin Target
8%
Pharmacology, Toxicology and Pharmaceutical Science
Antianemic Agent
100%
Chemotherapy Induced Anemia
100%
Recombinant Erythropoietin
91%
Randomized Clinical Trial
8%